Summary
Want to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab, a standard treatment option for lung cancer. The study drug rilvegostomig may help your immune system (body defense) fight your cancer.
Description
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Principal Investigator
Mohammad Alamgir
Study Coordinator
Lisa Luikart
Faculty Contact
Lisa Luikart - lisa.luikart@vandaliahealth.org
Departments
Sex
All
Age
18+
NCT Number
NCT06868277
IRB Number
25-1277
Phase(s)
3
Link
None